Breaking News, Financial News

Financial Report: GlaxoSmithKline 1Q

Growth in the quarter was driven by pandemic flu vaccine sales. Total vaccine sales were $2.1 billion, including $1.1 billion of H1N1 vaccine sales.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline 1Q 1Q Revenues: $11.3 billion (+13%) 1Q Earnings: $2.0 billion (+19%) Comments: Growth in the quarter was driven by pandemic flu vaccine sales. Total vaccine sales were $2.1 billion, including $1.1 billion of H1N1 vaccine sales. Pharmaceutical sales were up 14% to $9.4 billion. Sales of Seretide/Advair rose 9% to $2.0 billion. Flovent sales were $301.0 million (+5%). Avamys/Veramyst sales increased 52% to $71.0 million. Other strong performers included Tykerb (+62% to $8...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters